Motilal Oswal

Dishman Pharma

BSE SENSEX 17,729	S&P CNX 5,310	Rs11	17									Sell
Bloomberg	DISH IN	YEAR	NET SALES	PAT	EPS	EPS	P/E	P/BV	ROE	ROCE	EVI	EVI
Equity Shares (m)	81.3	END	(R\$ M)	(RS M)	(R\$)	GROWTH (2)	(X)	(X)	(*)	(3)	SALES	EBITDA
52-Week Range (Rs)	235/108	03/10A	9,154	1,157	14.2	-21.0	8.2	1.2	15.3	11.4	1.8	8.2
1,6,12 Rel. Perf. (%)	-9/-42/-53	03/11E	8,804	607	7.5	-47.5	15.7	1.1	7.4	6.8	1.9	12.0
M.Cap. (Rs b)	9.5	03/12E	9,841	368	4.5	-39.3	25.8	1.1	4.2	5.5	1.8	10.5
M.Cap. (US\$ b)	0.2	03/13E	11,669	720	8.9	95.6	13.2	1.0	7.8	7.7	1.5	8.2

- Dishman's 3QFY11 performance was significantly below our expectations. It reported a muted 4.3% YoY growth in revenue to Rs2.32b (v/s our estimate of Rs2.35b) while adjusted PAT declined 95% YoY to Rs17m (v/s our estimate of Rs209m), led by poor operational performance, and increase in depreciation and interest charges.
- CRAMS revenue declined 1.6% YoY to Rs1.58b (68% contribution to revenue) due to 16.1% YoY drop in the CRAMS revenue from India. MM business revenue reported 19.5% YoY growth to Rs736m, led by 29.9% YoY growth in Vitamin-D business.
- EBITDA declined 51% YoY to Rs253m while EBITDA margin contracted by 12.2 percentage points to 10.9% due to operating loss of Rs30.4m for CA. The local management of CA executed low-margin contracts to achieve topline target, resulting in poor profitability.
- Adjusted profit declined 94.6% YoY to Rs17m owing to poor operational performance, increase in depreciation charges due to ongoing capex, and higher interest cost on account of working capital borrowings.

Outlook and view: The macro environment for the CRAMS business remains favorable, given India's inherent cost advantage and chemistry skills. We believe that Dishman's India operations will benefit from increased outsourcing from India, given its strengthening MNC relations. However, the adverse business environment for CA and Euro depreciation will continue to impact earnings growth in FY11 and FY12. We expect revenue CAGR of 8.4%, EBITDA CAGR of 2.3% and earnings CAGR of -14.6% over FY10-13. The stock currently trades at 15.7x FY11E, 25.8x FY12E and 13.2x FY13E earnings. RoE will continue to be below 10% till new facilities and CRAMS contracts ramp up. We downgrade our rating from **Neutral** to **Sell**, with a revised target price of Rs89 (10x FY13E EPS).

Y/E MARCH		EY10	n			EY1	1		FY10	FY11E
	10	2Q		40	10	2Q	3Q	4QE		
Net Sales	2,277	2,174	2,223	2,479	2,019	2,128	2,318	2,339	9,154	8,804
YoY Change (%)	-3.5	-13.7	-21.2	-15.2	-11.3	-2.1	4.3	-5.6	-13.8	-3.8
Total Expenditure	1,745	1,677	1,710	1,984	1,574	1,759	2,064	1,993	7,116	7,390
EBITDA	532	498	513	495	445	369	253	346	2,038	1,414
Margins (%)	23.4	22.9	23.1	20.0	22.0	17.4	10.9	14.8	22.3	16.1
Depreciation	145	174	141	135	161	168	171	172	594	672
Interest	104	99	85	100	82	95	133	147	388	458
Other Income	155	59	32	25	104	203	61	30	270	398
PBT after EO Income	438	284	319	285	305	308	10	58	1,326	682
Tax	9	25	30	-10	17	14	-7	51	54	75
Deferred Tax	37	14	-32	96	17	0	0	-17	115	0
Rate (%)	10.5	14.0	-0.6	29.9	11.2	4.4	-68.1	59.6	12.8	11.0
Prior Period Adjustment	1	5	-10	-12	-1	12	1	0	-17	(
Reported PAT	391	240	331	212	272	283	17	23	1,174	607
Adj PAT	392	244	321	200	271	295	17	23	1,157	607
YoY Change (%)	41.5	725.7	-19.3	-73.7	-30.8	20.7	-94.6	-88.3	-21.0	-47.5
Margins (%)	17.2	11.2	14.4	8.0	13.4	13.9	0.8	1.0	12.6	6.9

Nimish Desai (NimishDesai @MotilalOswal.com); Tel: +91 22 3982 5406 / Amit Shah (Amit.Shah @MotilalOswal.com) + 91 22 3982 5423

Topline impacted by poor performance in CRAMS business

Dishman's 3QFY11 performance was significantly below our expectations. It reported a muted 4.3% YoY growth in revenue to Rs2.32b (v/s our estimate of Rs2.35b) while adjusted PAT declined 95% YoY to Rs17m (v/s our estimate of Rs209m), led by poor operational performance, and increase in depreciation and interest charges.

CRAMS revenue declined 1.6% YoY to Rs1.58b (68% contribution to revenue) due to 16.1% YoY drop in the CRAMS revenue from India. Carbogen AMCIS (CA) revenue grew 18.7% YoY to Rs795m on a low base (which was impacted by global credit crunch). MM business revenue reported 19.5% YoY growth to Rs736m, led by 29.9% YoY growth in Vitamin-D business. QUATs business grew just 10.3% YoY to Rs361m on a high base.

	3QFY11	3QFY10	% YoY	2QFY11	% QoQ
CRAMS	1,582	1,607	-1.6	1,608	-1.6
Dishman	787	938	-16.1	696	13.1
Carbogen AMCIS	795	670	18.7	912	-12.9
ММ	736	616	19.5	520	41.5
Vitamin-D	375	289	29.9	247	51.7
QUATs	361	327	10.3	273	32.3
Total	2,318	2,223	4.3	2,128	8.9

Sales mix (Rs m)


Source: Company/MOSL

EBITDA declines 51% YoY, significantly below our estimate

EBITDA declined 51% YoY to Rs253m while EBITDA margin contracted by 12.2 percentage points to 10.9% due to operating loss of Rs30.4m for CA. The local management of CA executed low-margin contracts to achieve topline target, resulting in poor profitability.

Dishman management indicated that it has taken corrective steps by changing the top management and targeting profitability improvement rather than topline growth. For the quarter, Dishman has reported the lowest ever quarterly EBITDA margin in the last four years.

EBITDA and Margin Trend



Source: Company

Adjusted profit declined 94.6% YoY to Rs17m owing to poor operational performance, increase in depreciation charges due to ongoing capex, and higher interest cost on account of working capital borrowings.

Management downgrades guidance for FY11

Management has downgraded FY11 revenue growth guidance from growth of 10% earlier to flat due to disappointing performance by CA, decline in CRAMS business from India and subdued performance of MM business. The company has guided for year-on-year decline in PAT as well. We are projecting revenue decline of 3.8% in FY11 considering the lower demand in QUATs business and contract research segment, impact of Euro depreciation and poor operational performance in 9MFY11 (revenue decline of 3.1%). Also, we estimate CA revenue at CHF75m v/s management guidance of ~CHF80m. We estimate overall consolidated PAT at Rs607m for FY11. Management has guided for 15% topline growth in non-CA business for FY12.

FY11 guidance Parameter Old New Remarks Guidance Guidance Overall Sales Growth (%) 10 Flat We forecast revenue decline of 3.8%YoY for FY11 due to muted performance in QUATs segment, slowdown at Carbogen AMCIS, lower contract research income and impact of Euro depreciation versus INR Carbogen AMCIS Revenue (CHF m) 90 80 We estimate 8.5% decline in revenues as performance of contract research business at Carbogen remains subdued. Company recorded revenues of CHF82m for FY10 PAT Growth (%) 10 Decline We estimate 47.5% decline in PAT due to depreciation of Euro, pressure on CA's profitability, increase in interest cost and 39%YoY decline in 9MFY11 PAT. Capex (Rs b) 1.25-1.5 1.5 2 new API units are coming up at Bavla.

Source: Company/MOSL


Euro depreciation to have negative impact on FY11 performance

Dishman derives ~50% of its revenue in Euro terms. In the last year, Euro has depreciated by 12% vis-à-vis the Rupee. The average Rupee/Euro rate stood at Rs60.9/Euro for 3QFY11 v/s Rs69.2/Euro for 3QFY10. If the situation worsens, it will have a negative impact on Dishman's performance. Our current estimates are based on Rs57/Euro.

CA reeling under pressure; management undertakes significant restructuring

CA has been reeling under pressure for the last two years due to global credit crunch. The company has lost some contract research business due to unavailability of funding for its customers to carry out research. In 3QFY11, CA reported operating loss due to adverse product mix. The local management at CA executed low margin contracts to boost revenue. Dishman's management has now commenced implementation of business restructuring to turn around the company. The existing CEO of CA has been fired and the management of Dishman has taken over CA's day-to-day working. It hopes to turn around the company in the next one year through cost restructuring (mainly manpower reduction) by targeting savings of CHF8m-9m. The management expects CA's topline to remain flat in FY11.

Motilal Oswal



Carbogen AMCIS revenue hit in FY10 and FY11, likely to decline further in FY12

Cutting earnings estimates by 37-64%

Based on poor 3QFY11 performance, we are cutting our revenue and PAT estimates to take into account subdued guidance for FY11, slow recovery in Carbogen AMCIS and flat revenue guidance for MM business. Accordingly, we are cutting FY11, FY12 and FY13 revenue estimates by 4.6%, 7.1% and 4.6%, and EPS estimates by 37.2%, 63.5% and 45.3%, respectively. We estimate FY11 EPS at Rs7.5 (down 47.5% YoY), FY12 EPS at Rs4.5 (de-growth of 39.3%) and FY13 EPS at Rs8.9 (up 95.6% on a very low base).

Outlook and view

The macro environment for the CRAMS business remains favorable, given India's inherent cost advantage and chemistry skills. We believe that Dishman's India operations will benefit from increased outsourcing from India, given its strengthening MNC relations. However, the adverse business environment for CA and Euro depreciation will continue to impact earnings growth in FY11 and FY12. We expect revenue CAGR of 8.4%, EBITDA CAGR of 2.3% and earnings CAGR of -14.6% over FY10-13. The stock currently trades at 15.7x FY11E, 25.8x FY12E and 13.2x FY13E earnings. RoE will continue to be below 10% till new facilities and CRAMS contracts ramp up. We downgrade our rating from Neutral to **Sell**, with a revised target price of Rs89 (10x FY13E EPS).

Dishman Pharma: an investment profile

Company description

Dishman Pharma is one of the leading players in the CRAMS segment and has developed strong relationships with innovator companies. It has established presence across the CRAMS value chain and is also one of the largest manufacturers of QUATs globally.

Key investment arguments

- We expect Dishman to benefit from the expected increase in pharmaceutical outsourcing from India over the next few years.
- Dishman's focus on establishing relationships with new customers and reducing its dependence on Solvay has begun bearing fruits. It has signed supply contracts with AstraZeneca and is in advanced discussions with large companies like GSK, Novartis, and J&J for outsourcing deals.

Key investment risks

- Since Dishman derives ~50% of its revenue in Euro, the recent depreciation in Euro is likely to have negative impact on the performance of the company.
- Dishman has been suffering from de-stocking of inventory carried out by its large customers and declining demand from Carbogen AMCIS customers due to unavailability of funding. This situation may continue in the near future, thereby impacting Dishman's performance.

Comparative valuations

		Dishman	Divis
P/E (x)	FY11E	15.7	23.4
	FY12E	25.8	19.3
P/BV (x)	FY11E	1.1	4.7
	FY12E	1.1	4.0
EV/Sales (x)	FY11E	1.9	7.3
	FY12E	1.8	6.1
EV/EBITDA (x)	FY11E	12.0	19.4
	FY12E	10.5	15.4

Shareholding pattern (%)

	Dec-10	Sep-10	Dec-09
Promoter	60.9	60.9	60.8
Domestic Inst	9.3	11.1	12.5
Foreign	9.2	9.7	11.3
Others	20.5	18.4	15.4

Recent developments

Has raised Rs750m through the issue of non-convertible debentures.

Valuation and view

- We expect Dishman to be a key beneficiary of the increased pharmaceutical outsourcing from India given its strong relationships with global innovator pharmaceutical companies.
- Valuations at 15.7x FY11E, 25.8xFY12E and 13.2x FY13E earnings.
- We downgrade our recommendation to **Sell**.

Sector view

- India is on the threshold of a significant opportunity in the contract manufacturing space. We expect increased outsourcing from India as it offers a unique proposition of low costs coupled with chemistry and regulatory skills.
- High entry barriers will ensure that the top 6-7 players will command a disproportionate share of this opportunity.

EPS: MOSL forecast v/s consensus (Rs)

	MOSL	Consensus	Variation
	Forecast	Forecast	(%)
FY11	7.5	13.4	-44.2
FY12	4.5	16.8	-73.2

Target Price and Recommendation

Current	Target *	Upside	Reco.
Price (Rs)	Price (Rs)	(%)	
117	89	-23.9	Sell

Stock performance (1 year)



MOTILAL OSWAL

Financials and Valuation

INCOME STATEMENT				(Rs	Million)
Y/E MARCH	2009	2010	2011E	2012E	2013E
Net Sales	10,624	9,154	8,804	9,841	11,669
Change (%)	32.3	-13.8	-3.8	11.8	18.6
Total Expenditure	8,009	7,116	7,390	8,142	9,486
% of Sales	75.4	77.7	83.9	82.7	81.3
EBITDA	2,615	2,038	1,414	1,699	2,183
Margin (%)	24.6	22.3	16.1	17.3	18.7
Depreciation	629	594	672	770	830
EBIT	1,985	1,444	742	929	1,353
Int. and Finance Charges	459	388	458	546	555
Other Income - Rec.	48	270	398	50	60
PBT before EO Expense	1,575	1,326	682	433	857
Extra Ordinary Expense/(Incom-	0	0	0	0	0
PBT after EO Expense	1,575	1,326	682	433	857
Current Tax	45	54	75	65	137
Deferred Tax	66	115	0	0	0
Tax Rate (%)	7.1	12.8	11.0	15.0	16.0
Reported PAT	1,463	1,157	607	368	720
PAT Adj for EO Items	1,463	1,157	607	368	720
Change (%)	20.4	-21.0	-47.5	-39.3	95.6
Margin (%)	13.77	12.64	6.89	3.74	6.17

BALANCE SHEET				(Rs I	Million)
Y/E MARCH	2009	2010	2011E	2012E	2013E
Equity Share Capital	161	161	161	161	161
Fully Diluted Equity Capital	163	163	163	163	163
Total Reserves	6,981	7,808	8,366	8,705	9,353
Net Worth	7,143	7,969	8,528	8,866	9,514
Deferred liabilities	208	316	316	316	431
Total Loans	7,237	7,739	9,153	9,098	9,256
Capital Employed	14,588	16,025	17,997	18,280	19,202
Gross Block	7,979	9,320	10,820	11,820	12,820
Less: Accum. Deprn.	1,953	2,481	3,153	3,153	3,747
Net Fized Assets	6,027	6,839	7,667	8,667	9,073
Capital WIP	2,227	3,574	3,574	3,574	3,574
Investments	14	14	14	14	14
Goodwill	1,754	1,590	1,590	1,590	1,590
Curr. Assets	6,850	5,880	7,429	6,826	7,858
Inventory	3,040	2,423	2,465	2,706	3,151
Account Receivables	1,494	1,131	1,233	1,329	1,517
Cash and Bank Balance	452	455	1,706	724	857
Loans & Advances	1,865	1,871	2,025	2,067	2,334
Curr. Liability & Prov.	2,284	1,873	2,278	2,392	2,908
Account Payables	1,588	1,617	1,585	1,771	2,100
Provisions	696	256	693	621	808
Net Current Assets	4,566	4,007	5,151	4,434	4,950
Appl. of Funds	14,588	16,025	17,997	18,280	19,202

E: MOSL Estimates

Y/E MARCH	2009	2010	2011E	2012E	2013E
Basic (Rs)					
EPS (fully diluted)	18.0	14.2	7.5	4.5	8.9
Cash EPS (fully diluted)	25.7	21.5	15.7	14.0	19.1
BV/Share	88.5	98.8	105.7	109.9	117.9
DPS	1.2	1.2	0.5	0.3	0.8
Payout (%)	7.7	9.8	8.0	8.0	10.0
Valuation (x)					
P/E (fully diluted)	6.5	8.2	15.7	25.8	13.2
Cash P/E (fully diluted)	4.5	5.4	7.4	8.4	6.1
P/BV	1.3	1.2	1.1	1.1	1.0
EV/Sales	1.5	1.8	1.9	1.8	1.5
EVIEBITDA	6.2	8.2	12.0	10.5	8.2
Dividend Yield (%)	1.0	1.0	0.4	0.3	0.7
Return Ratios (%)					
RoE	22.7	15.3	7.4	4.2	7.8
RoCE	15.2	11.4	6.8	5.5	7.7
Vorking Capital Ratios					
Fixed Asset Turnover (x)	1.9	1.4	1.2	1.2	1.3
Debtor (Days)	51	45	51	49	47
Inventory (Days)	104	97	102	100	- 99
Working Capital Turnover (Day:	141	142	143	138	128
Leverage Ratio (x)					
Current Ratio	3.0	3.1	3.3	2.9	2.7
Debt/Equity	1.0	1.0	1.1	1.0	1.0

RATIOS

CASH FLOW STATEMENT				(Rs I	Million)
Y/E MARCH	2009	2010	2011E	2012E	2013E
Oper. Profit/(Loss) before Tax	2,615	2,038	1,414	1,699	2,183
Interest/Dividends Recd.	48	270	398	50	60
Direct Taxes Paid	-45	-54	-75	-65	-137
(Inc)/Dec in WC	-371	562	107	-265	-383
CF from Operations	2,246	2,816	1,844	1,419	1,722
EO Expense ł (Income)	0	0	0	0	0
CF from Operating incl El	2,246	2,816	1,844	1,419	1,722
(inc)/dec in FA	-2,514	-2,524	-1,500	-1,000	-1,000
(Pur)/Sale of Investments	-1	0	0	0	0
CF from Investments	-2,514	-2,524	-1,500	-1,000	-1,000
Issue of shares	2	0	0	0	0
(Inc)/Dec in Debt	657	503	1,414	-56	159
Interest Paid	-459	-388	-458	-546	-555
Dividend Paid	-113	-113	-49	-29	-72
Others	261	-290	0	-770	-121
CF from Fin. Activity	348	-288	908	-1,401	-590
Inc/Dec of Cash	81	3	1,252	-982	133
Add: Beginning Balance	371	452	455	1,706	724
Closing Balance	451	455	1,706	724	857

MOTILAL OSWAL

NOTES



For more copies or other information, contact **Institutional:** Navin Agarwal. **Retail:** Manish Shah Phone: (91-22) 39825500 Fax: (91-22) 22885038. E-mail: reports@motilaloswal.com

Motilal Oswal Securities Ltd, 3rd Floor, Hoechst House, Nariman Point, Mumbai 400 021

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Motilal Oswal Securities Limited (*hereinafter referred as MOSt*) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form.

The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon such. MOSt or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

MOSt and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

This information is subject to change without any prior notice. MOSt reserves the right to make modifications and alternations to this statement as may be required from time to time. Nevertheless, MOSt is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.